Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 10/20 | 0.59 |
| ▸ | CYSLTR1 | Q9Y271 | 10/20 | 0.59 |
| ▸ | BID | P55957 | 3/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.48 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.48 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.48 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.48 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7916115 | 0.98 | CYSLTR2 (0.62) | CYSLTR2CYSLTR1BIDMCL1BCL2L1 | |
| SCHEMBL4029728 | 0.88 | CYSLTR2 (0.46) | CYSLTR2CYSLTR1PPARGPPARA | |
| SCHEMBL11011751 | 0.86 | BID (0.51) | CYSLTR2CYSLTR1BIDMCL1BCL2L1 | |
| SCHEMBL9667336 | 0.86 | CYSLTR2 (0.56) | CYSLTR2CYSLTR1BIDMCL1BCL2L1 | |
| SCHEMBL9068158 | 0.85 | BID (0.54) | CYSLTR2CYSLTR1BIDMCL1BCL2L1 | |
| SCHEMBL28373053 | 0.84 | CYSLTR2 (0.59) | CYSLTR2CYSLTR1BIDMCL1BCL2L1 | |
| SCHEMBL11011747 | 0.84 | CYSLTR2 (0.46) | CYSLTR2CYSLTR1 | |
| SCHEMBL5570575 | 0.83 | LMNA (0.48) | CYSLTR2CYSLTR1 | |
| SCHEMBL3266290 | 0.83 | LMNA (0.48) | CYSLTR2CYSLTR1 | |
| SCHEMBL10435204 | 0.83 | CYSLTR2 (0.62) | CYSLTR2CYSLTR1BIDMCL1BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106692144-A | Compositions and methods for prophylaxis and treatment of addictions | 奥默罗斯公司 | 2017-05-24 | — | — | CN | disclosed |
| US-20040044075-A1 | Alpha acyloxyacetamides for kallikrein and urokinase inhibition | GENZYME CORPORATION | 2004-03-04 | — | — | US | disclosed |
| WO-2003101941-A2 | ALPHA ACYLOXYACETAMIDES FOR KALLIKREIN AND UROKINASE INHIBITION | GENZYME CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044075-A1 | Alpha acyloxyacetamides for kallikrein and urokinase inhibition | KLK1, KLK2, KLKB1 | CYSLTR2 207/4885CYSLTR1 314/4885BID 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.